Oyster Point Pharma Overview
Latest ROE for Oyster Point Pharma: 851.15% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow851.15%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, OYST shows a ROE of 851.15%. That is above the Healthcare sector average of 11.15%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 11.15%. Oyster Point Pharma is at 851.15%, which is higher that average. That is roughly 7530.8% above the sector mean. Use the comparison chart on this page to see how OYST stacks up against individual peers as well.
Check the historical chart to see whether OYST's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Oyster Point Pharma with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Oyster Point Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 851.15%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 11.15%, while OYST is at 851.15%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
